- Home
- CIM vs MDXG Comparison
CIM vs MDXG Comparison
Compare CIM & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- MDXG
- Stock Information
- Founded
- CIM 2007
- MDXG 2006
- Country
- CIM United States
- MDXG United States
- Employees
- CIM N/A
- MDXG N/A
- Industry
- CIM Real Estate Investment Trusts
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- MDXG Health Care
- Exchange
- CIM Nasdaq
- MDXG Nasdaq
- Market Cap
- CIM 1.1B
- MDXG 877.4M
- IPO Year
- CIM 2007
- MDXG N/A
- Fundamental
- Price
- CIM $14.12
- MDXG $6.67
- Analyst Decision
- CIM Buy
- MDXG Strong Buy
- Analyst Count
- CIM 3
- MDXG 2
- Target Price
- CIM $15.50
- MDXG $12.50
- AVG Volume (30 Days)
- CIM 561.8K
- MDXG 771.8K
- Earning Date
- CIM 08-06-2025
- MDXG 07-30-2025
- Dividend Yield
- CIM 10.52%
- MDXG N/A
- EPS Growth
- CIM N/A
- MDXG N/A
- EPS
- CIM 1.52
- MDXG 0.27
- Revenue
- CIM $326,755,000.00
- MDXG $352,375,000.00
- Revenue This Year
- CIM $18.94
- MDXG $9.55
- Revenue Next Year
- CIM $3.05
- MDXG $11.43
- P/E Ratio
- CIM $9.26
- MDXG $25.11
- Revenue Growth
- CIM 11.90
- MDXG 5.34
- 52 Week Low
- CIM $9.85
- MDXG $5.47
- 52 Week High
- CIM $16.89
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- CIM 55.31
- MDXG 57.60
- Support Level
- CIM $14.09
- MDXG $5.86
- Resistance Level
- CIM $14.43
- MDXG $7.05
- Average True Range (ATR)
- CIM 0.25
- MDXG 0.24
- MACD
- CIM -0.03
- MDXG 0.11
- Stochastic Oscillator
- CIM 59.24
- MDXG 69.20
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.